Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients (Oligo-PRESTO)
Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients - a GETUG-AFU Phase III Randomized Controlled Trial
Sponsor: UNICANCER
This PHASE3 trial investigates Oligometastatic Hormone Sensitive Prostate Cancer and is currently ongoing. UNICANCER leads this study, which shows 12 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Jul 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE3
▶ Show 7 earlier versions
-
Mar 2023 — May 2024 [monthly]
Recruiting PHASE3
-
Jun 2022 — Mar 2023 [monthly]
Recruiting PHASE3
-
Sep 2021 — Jun 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE3
Status: Suspended → Recruiting
-
May 2020 — Oct 2020 [monthly]
Suspended PHASE3
Status: Not Yet Recruiting → Suspended
-
Nov 2019 — May 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- UNICANCER
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Avignon, France , Bordeaux, France , Brest, France , Caen, France , Clermont-Ferrand, France , Creil, France , Créteil, France , Fort-de-France, Martinique , Jossigny, France , Lille, France and 21 more locations